Dec. 18 (UPI) -- The Coalition for Epidemic Preparedness Innovations announced it will invest up to $54.3 million with Moderna to fund a Phase 3 trial of its bird flu vaccine.
The vaccine is an mRNA-based H5 influenza candidate for bird flu in humans.
CEPI, based in Oslo, Norway, is a public-private partnership whose mission is to speed the development of vaccines and other biologic countermeasures against epidemic and pandemic threats. The organization has a "100 Days Mission," with the goal of being able to create vaccines within 100 days of a new disease threat. It has supported the development of more than 70 vaccine candidates or platform technologies.
"We are proud to have the support of CEPI to advance our pandemic influenza vaccine candidate, research that is critical to our commitment to pandemic preparedness," said Stéphane Bancel, CEO of Moderna, in a statement. "mRNA technology can play a vital role in addressing emerging health threats quickly and effectively, and we look forward to continuing our partnership with CEPI as we advance our health security portfolio, and in parallel, further the 100 Days Mission."
Related
